89R9085 LRM-D
 
  By: Vasut H.B. No. 5521
 
 
 
A BILL TO BE ENTITLED
 
AN ACT
  relating to the possession and administration of an opioid
  antagonist by certain entities.
         BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:
         SECTION 1.  Subchapter A, Chapter 773, Health and Safety
  Code, is amended by adding Section 773.018 to read as follows:
         Sec. 773.018.  POSSESSION AND ADMINISTRATION OF OPIOID
  ANTAGONIST. (a)  In this section, "live music venue" means a
  business with a space for live music and a primary revenue source of
  patron attendance to live music performances. The term includes a
  concert hall and indoor or outdoor stadium.
         (b)  This section applies to:
               (1)  an amusement park, as defined by Section 46.03,
  Penal Code;
               (2)  a live music venue;
               (3)  a sports venue, as defined by Section 504.151,
  Local Government Code; and
               (4)  subject to Subsection (c), other entities the
  executive commissioner by rule designates as an entity that
  benefits from the possession and administration of opioid
  antagonists.
         (c)  This section does not apply to a governmental entity.
         (d)  An entity subject to this section may adopt a policy
  regarding the maintenance, administration, and disposal of opioid
  antagonists.  The policy must authorize the administration of an
  opioid antagonist for a person reasonably believed to be
  experiencing an opioid overdose on the entity's premises only by an
  entity employee or volunteer who is authorized and trained to
  administer the opioid antagonist.
         (e)  The executive commissioner shall adopt rules regarding
  an entity's maintenance, administration, and disposal of opioid
  antagonists under this section.  The rules must establish:
               (1)  the number and dosages of the opioid antagonists
  available at each entity;
               (2)  the process for each entity to regularly verify
  its inventory of opioid antagonists for replacement of expired
  opioid antagonists; and
               (3)  the training required for an entity employee or
  volunteer to administer an opioid antagonist.
         (f)  Each entity that adopts a policy under Subsection (d)
  must have at least one entity employee or volunteer authorized and
  trained to administer an opioid antagonist present during all hours
  the entity is open to the public or the population the entity
  serves, as applicable.
         (g)  The entity's supply of opioid antagonists must:
               (1)  be stored in a secure location and in accordance
  with the manufacturer's instructions; and
               (2)  be easily accessible to an entity employee or
  volunteer who is authorized and trained to administer an opioid
  antagonist.
         (h)  Each entity that adopts a policy under Subsection (d) is
  responsible for training the entity's employees and volunteers in
  the administration of an opioid antagonist.  The training must:
               (1)  include information on:
                     (A)  the signs and symptoms of an opioid overdose;
                     (B)  the recommended opioid antagonist dosages
  for an adult and a child;
                     (C)  the administration of an opioid antagonist;
                     (D)  the implementation of any necessary
  emergency procedures after administration of an opioid antagonist;
  and
                     (E)  the proper disposal of a used or expired
  opioid antagonist; and
               (2)  be completed annually in a formal training session
  or through online education.
         (i)  Each entity shall maintain records on the training
  completed by each entity employee and volunteer under this section.
         (j)  An entity, entity employee or volunteer, or other person
  who in good faith acts or fails to act as authorized under this
  section, including by administering an opioid antagonist as
  authorized in a policy adopted under this section, is immune from
  civil or criminal liability or disciplinary action resulting from
  that act or failure to act, including:
               (1)  supervising or delegating the administration of an
  opioid antagonist;
               (2)  possessing, maintaining, storing, or disposing of
  an opioid antagonist;
               (3)  administering, or assisting in the administration
  of, an opioid antagonist;
               (4)  providing training, consultation, or advice in the
  development, adoption, or implementation of policies, guidelines,
  or plans; or
               (5)  any other act authorized or required under this
  section.
         (k)  The immunities and protections provided by this section
  are in addition to other immunities or limitations of liability
  provided by law.
         (l)  Notwithstanding any other law, this section does not
  create a civil, criminal, or administrative cause of action or
  liability or create a standard of care, obligation, or duty that
  provides a basis for a cause of action for an act or omission under
  this section.  A cause of action does not arise from an act or
  omission described by this section.
         (m)  An act or failure to act by an entity employee or
  volunteer under this section, including an act or failure to act
  under related entity policies and procedures, is the exercise of
  judgment or discretion on the part of the entity employee or
  volunteer and is not considered to be a ministerial act for purposes
  of liability of the entity.
         SECTION 2.  This Act takes effect September 1, 2025.